JP2020522506A - 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 - Google Patents

前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 Download PDF

Info

Publication number
JP2020522506A
JP2020522506A JP2019566594A JP2019566594A JP2020522506A JP 2020522506 A JP2020522506 A JP 2020522506A JP 2019566594 A JP2019566594 A JP 2019566594A JP 2019566594 A JP2019566594 A JP 2019566594A JP 2020522506 A JP2020522506 A JP 2020522506A
Authority
JP
Japan
Prior art keywords
group
psma
compound
tumor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019566594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522506A5 (enExample
Inventor
レイ サンギータ
レイ サンギータ
ジー ポンパー マーティン
ジー ポンパー マーティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2020522506A publication Critical patent/JP2020522506A/ja
Publication of JP2020522506A5 publication Critical patent/JP2020522506A5/ja
Priority to JP2023127925A priority Critical patent/JP2023159182A/ja
Priority to JP2024221155A priority patent/JP2025041719A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/24—Lead compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019566594A 2017-05-30 2018-05-30 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 Pending JP2020522506A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023127925A JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2024221155A JP2025041719A (ja) 2017-05-30 2024-12-17 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512515P 2017-05-30 2017-05-30
US62/512,515 2017-05-30
PCT/US2018/035220 WO2018222778A1 (en) 2017-05-30 2018-05-30 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023127925A Division JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Publications (2)

Publication Number Publication Date
JP2020522506A true JP2020522506A (ja) 2020-07-30
JP2020522506A5 JP2020522506A5 (enExample) 2021-01-07

Family

ID=64455570

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019566594A Pending JP2020522506A (ja) 2017-05-30 2018-05-30 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2023127925A Pending JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2024221155A Pending JP2025041719A (ja) 2017-05-30 2024-12-17 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023127925A Pending JP2023159182A (ja) 2017-05-30 2023-08-04 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤
JP2024221155A Pending JP2025041719A (ja) 2017-05-30 2024-12-17 前立腺がんの内部放射線治療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤

Country Status (5)

Country Link
US (2) US11478558B2 (enExample)
EP (1) EP3630733A4 (enExample)
JP (3) JP2020522506A (enExample)
CN (2) CN118146170A (enExample)
WO (1) WO2018222778A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120172924A (zh) * 2018-02-06 2025-06-20 约翰霍普金斯大学 用于癌症放射治疗的psma靶向的放射性卤化尿素-聚氨基羧酸盐
CN114364405B (zh) * 2019-04-26 2024-07-16 五一一制药股份有限公司 作为诊断剂和放射性核素治疗剂的前列腺特异性膜抗原(psma)抑制剂
EP3993838A1 (en) * 2019-07-02 2022-05-11 Novartis AG Prostate specific membrane antigen (psma) ligands and uses thereof
CN114341118A (zh) * 2019-07-02 2022-04-12 先进加速器应用意大利公司 前列腺特异性膜抗原(psma)配体及其用途
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
JP2023522983A (ja) * 2020-04-24 2023-06-01 ラジオメディックス インコーポレイテッド 前立腺がんの診断および処置のための組成物、キットおよび方法
CA3178858A1 (en) * 2020-05-06 2021-11-11 Cornell University Copper-containing theragnostic compounds and methods of use
EP4196175A4 (en) * 2020-08-14 2025-07-30 Clarity Pharmaceuticals Ltd RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
EP4204020A1 (en) * 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
US20230321285A1 (en) * 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (en) * 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
US20240131206A1 (en) * 2020-12-04 2024-04-25 The Regents Of The University Of California Peptide receptor radionuclide therapy
CN113077840B (zh) * 2021-04-21 2023-01-31 四川大学 基于药效团与alpha-碳特征的金属酶活性位点对比方法
US20250161502A1 (en) * 2022-02-09 2025-05-22 Novartis Ag Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
CA3258344A1 (en) * 2022-06-07 2023-12-14 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
WO2024169037A1 (zh) * 2023-02-16 2024-08-22 无锡诺宇医药科技有限公司 Psma靶向放射性药物及其合成和应用
WO2024243315A2 (en) * 2023-05-22 2024-11-28 Actinium Pharmaceuticals, Inc. Multi-arm bifunctional chelators

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065902A2 (en) * 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma
WO2013082338A1 (en) * 2011-11-30 2013-06-06 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof
JP2014524419A (ja) * 2011-08-05 2014-09-22 モレキュラー インサイト ファーマシューティカルズ 放射標識された前立腺特異的膜抗原阻害剤
WO2015055318A1 (en) * 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015171792A1 (en) * 2014-05-06 2015-11-12 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
WO2016030329A1 (en) * 2014-08-24 2016-03-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
JP2019508374A (ja) * 2015-12-31 2019-03-28 ファイブ イレブン ファーマ インコーポレイテッド イメージング及び治療のための尿素系前立腺特異的膜抗原（ｐｓｍａ）阻害剤
JP2019519467A (ja) * 2016-03-22 2019-07-11 ザ・ジョンズ・ホプキンス・ユニバーシティ 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2921482B1 (en) * 2007-06-26 2018-09-05 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
US9422234B2 (en) 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
EP3222617B1 (en) * 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
JP6468602B2 (ja) 2013-01-14 2019-02-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド トリアジン系放射性医薬品及び放射線造影剤
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP2017530109A (ja) * 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護
US11420910B2 (en) * 2014-10-30 2022-08-23 Katholieke Universitet Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065902A2 (en) * 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma
JP2014524419A (ja) * 2011-08-05 2014-09-22 モレキュラー インサイト ファーマシューティカルズ 放射標識された前立腺特異的膜抗原阻害剤
WO2013082338A1 (en) * 2011-11-30 2013-06-06 The Johns Hopkins University Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof
WO2015055318A1 (en) * 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015171792A1 (en) * 2014-05-06 2015-11-12 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
WO2016030329A1 (en) * 2014-08-24 2016-03-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
JP2019508374A (ja) * 2015-12-31 2019-03-28 ファイブ イレブン ファーマ インコーポレイテッド イメージング及び治療のための尿素系前立腺特異的膜抗原（ｐｓｍａ）阻害剤
JP2019519467A (ja) * 2016-03-22 2019-07-11 ザ・ジョンズ・ホプキンス・ユニバーシティ 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
JP7073270B2 (ja) * 2016-03-22 2022-05-23 ザ・ジョンズ・ホプキンス・ユニバーシティ 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BANERJEE, SANGEETA R.; ET AL: "Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51(15),, JPN6021008600, 2008, pages 4504 - 4517, ISSN: 0004779144 *
BANERJEE, SANGEETA RAY; ET AL: "Synthesis and Evaluation of GdIII-Based Magnetic Resonance Contrast Agents for Molecular Imaging of", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 54(37),, JPN6021008605, 2015, pages 10778 - 10782, ISSN: 0004779146 *
BENESOVA, MARTINA; BAUDER-WUEST, ULRIKE; SCHAEFER, MARTIN; KLIKA, KAREL D.; MIER, WALTER; HABERKORN,: "Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting an", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59(5),, JPN6021008594, 2016, pages 1761 - 1775, ISSN: 0004779142 *
CLEEREN, FREDERIK; LECINA, JOAN; BILLAUD, EMILIE M. F.; AHAMED, MUNEER; VERBRUGGEN, ALFONS; BORMANS,: "New Chelators for Low Temperature Al18F-Labeling of Biomolecules", BIOCONJUGATE CHEMISTRY, vol. 27(3),, JPN6021008603, 2016, pages 790 - 798, ISSN: 0004779145 *
EDER, MATTHIAS; SCHAEFER, MARTIN; BAUDER-WUEST, ULRIKE; HULL, WILLIAM-EDMUND; WAENGLER, CARMEN; MIER: "68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging", BIOCONJUGATE CHEMISTRY, vol. 23(4),, JPN6021008590, 2012, pages 688 - 697, ISSN: 0004779141 *
SCHAEFER, MARTIN; BAUDER-WUEST, ULRIKE; LEOTTA, KARIN; ZOLLER, FREDERIC; MIER, WALTER; HABERKORN, UW: "A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of p", EJNMMI RESEARCH, vol. 2(1),, JPN6021008609, 2012, pages 23, ISSN: 0004779147 *
SHALLAL, HASSAN M.; MINN, IL; BANERJEE, SANGEETA R.; LISOK, ALA; MEASE, RONNIE C.; POMPER, MARTIN G.: "Heterobivalent Agents Targeting PSMA and Integrin-αvβ3", BIOCONJUGATE CHEMISTRY, vol. 25(2),, JPN6021008595, 2014, pages 393 - 405, ISSN: 0004779143 *

Also Published As

Publication number Publication date
CN111032632A (zh) 2020-04-17
EP3630733A1 (en) 2020-04-08
CN111032632B (zh) 2024-04-12
US11478558B2 (en) 2022-10-25
CN118146170A (zh) 2024-06-07
US20230147035A1 (en) 2023-05-11
EP3630733A4 (en) 2021-03-17
WO2018222778A1 (en) 2018-12-06
US20200306391A1 (en) 2020-10-01
JP2023159182A (ja) 2023-10-31
JP2025041719A (ja) 2025-03-26

Similar Documents

Publication Publication Date Title
US20230147035A1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
JP2020522506A5 (enExample)
JP7630149B2 (ja) Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤
JP7073270B2 (ja) 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
EP3609544B1 (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
EP3856261A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
WO2016065145A2 (en) Psma targeted reversed carbamates and methods of use thereof
US20210040126A1 (en) 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
US11078166B2 (en) Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof
WO2016149188A1 (en) 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
WO2025042989A1 (en) Psma-based albumin binding agents for targeted radionuclide therapy of prostate cancer

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210527

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230922

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107